Sydney, Feb 26, 2026, 17:55 AEDT — The market has closed.
- Sigma Healthcare dropped 1.7%, shares moving between A$2.93 and A$3.20 before settling lower.
- The Chemist Warehouse owner reported half-year earnings and revenue up by double digits.
- Traders are eyeing early second-half sales momentum, plus keeping tabs on the March dividend schedule.
Sigma Healthcare Ltd (ASX:SIG) dropped 1.7% to A$2.94 by Thursday’s close, giving up earlier gains. Shares kicked off at A$3.15, peaked at A$3.20, then reversed lower into the final bell.
The half-year numbers take on extra weight as one of the initial clear milestones for the newly combined Sigma–Chemist Warehouse group. They arrive toward the tail-end of Australia’s reporting season, a point when investors often move past the “beat” stories and zero in on cash flow and operational follow-through.
Friday brings another test: Was that sharp intraday swing in the stock just a blip, or does it signal something deeper? Retail-oriented stocks remain in limbo, with scant data so far on the strength of the consumer.
The S&P/ASX 200 closed roughly 0.5% higher, so Sigma’s late drop stood out as stock-specific rather than a sign of broader weakness.
Sigma reported that normalised EBIT climbed 18.7% to A$582.9 million for the half-year ended Dec. 31, as it stripped out merger and other one-off effects. Normalised net profit after tax landed at A$392.0 million, up 19.2%. Pro-forma revenue jumped 14.9%, reaching A$5.5 billion, the company said.
Sales at Chemist Warehouse-branded stores in Australia jumped 17.2% to A$5.1 billion, with like-for-like sales up 15.0%, Pharmacy Daily said. The publication pointed to strong demand for GLP-1 medicines—drugs used for diabetes and weight loss—as a key driver. Chief executive Vikesh Ramsunder described the integration process as moving forward “with discipline,” per the report. Pharmacy Daily
Even so, the day’s price swings underlined how “good” figures can hit differently. When growth hangs on hot sectors such as GLP-1 drugs, it’s not immune to losing steam—especially with tougher year-over-year comps. Integration? That tends to dredge up fresh costs right when you least want them.
Investors are set to scrutinize if the revamped stores and brand tweaks actually stabilize margins—not just speed up sales growth. The other thing? Early in the second half, the trading update landed; they’ll see if it really stands up after markets get beyond that initial look.
Sigma’s half-year filing showed statutory sales revenue at A$5.51 billion, with NPAT attributable to owners landing at A$379.8 million. The company noted that prior-year comparatives only reflect Chemist Warehouse, following the reverse acquisition that wrapped up on Feb. 12, 2025. Sigma also declared a fully franked interim dividend of 2.0 Australian cents per share, carrying Australian tax credits. The ex-dividend date is set for March 4, the record date comes a day later on March 5, and shareholders are scheduled to be paid on March 20.
